电话:010-83575130
X本团队近10余年来建立包括类风湿关节炎、系统性红斑狼疮等多种疾病的大型临床数据库及前瞻性研究队列。建立了大型的生物学标本库。具有完备的实验室设备。近5年在国际和国内杂志累积发表论文200余篇,先后主持国家级、北京市、各部委及院校级科研项目共15项,先后培养硕士及博士研究生40余名。其中3人获北京大优秀毕业生,1人获北京市优秀毕业生。在2014-2023年度中国医院科技量值(厂罢贰惭)排行榜中连续10次上榜,最好排名第6位。复旦榜专科声誉排名近5年稳步上升,20203年升至第10名。近3年共获得省部级、市级及校院级科研基金资助15项,总金额227万。共发表核心期刊59片,厂颁滨文章64篇。
类风湿关节炎滑膜成纤维样细胞(RA-FLS)通过异常增殖、促炎及骨破坏作用参与RA发病。但其调控机制仍不清楚。我们发现,细胞基质蛋白Cyr61可通过HIF-1α/BNIP3/自噬通路促进RA-FLS过度活化。但Cyr61促进RA-FLS高表达HIF-1α的机制尚不清楚。HIF-1α的上游通路包括MAPK和PI3K-Akt通路。我们的转录组学研究发现,Cyr61可激活RA-FLS的MAPK和PI3K-Akt通路。本研究拟通过检测RA患者滑膜组织标本中MAPK和PI3K-Akt通路蛋白的表达;从细胞水平验证低氧环境下Cyr61对RA-FLS MAPK和PI3K-Akt的影响;从分子水平验证抑制MAPK和PI3K-Akt表达后Cyr61对RA-FLS中HIF-1α影响的变化;通过动物实验验证MAPK和PI3K-Akt通路抑制剂对关节炎模型小鼠的治疗作用,从而为探索RA新的治疗靶点提供理论依据。
颁测谤61促进类风湿关节炎发病的机制研究
1、timi天美传孟若羽青年培育基金,HIF-1alpha通过介导滑膜成纤维细胞的自噬促进类风湿关节炎发病的机制研究,2023/11-2023/12, 5万,已结题,主持
2、国家自然科学青年基金,81901642,Cyr61促进类风湿关节炎发病的机制研究,2020/01-2022/12, 20万,已结题,主持
3、timi天美传孟若羽青年临床基金专项,强化治疗对达到临床治疗目标的类风湿关节炎患者亚临床滑膜炎疗效的随机对照研究,2017/07-2018/07, 15万,已结题,主持
1. Juan Zhao, Guangtao Li, Jing Xu, Xiaohui Zhang, Zhuoli Zhang*. Performance of the American College of Rheumatology /European League Against Rheumatism 2010 criteria for the diagnosis of rheumatoid arthritis in Chinese Patients. Joint Bone Spine. 2013 Oct;80(5):482-7
2. Juan Zhao, Juan Guo, Lifang Wang, Wei Zhou, Zhuoli Zhang*. The role of a proliferation inducing ligand (APRIL) in the pathogenesis of Rheumatoid Arthritis. Scand J Rheumatol. 2014;43:462–469.
3. Juan Zhao ; Juan Li; Zhuoli Zhang , Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study, Scandinavian Journal of Rheumatology, 2018.9.30, 1(1): 1~7
4. Zhao J, Ye X, Zhang Z.The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs. Clin Rheumatol. 2020 Sep;39(9):2573-2581.
5. Zhao J, Wang Y, Geng Y, Zhang X, Deng X, Ji L, Song Z, Zhang Z.Intensive therapy alleviates subclinical synovitis on ultrasound and disease activity and reduces flare in rheumatoid arthritis patients who have achieved clinical target - a randomized controlled trial. Semin Arthritis Rheum. 2020 Aug;50(4):673-679.
6. Zhao J, Zhou W, Wu Y, Ji P, Yang L, Yan X, Zhang Z. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study). BMC Med Inform Decis Mak. 2021 Mar 4;21(1):83.
7. Zhao J, Zhou W, Wu Y, Yan X, Yang L, Zhang Z. Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study). Chin Med J (Engl). 2022 Sep 20;135(18):2200-2209.
8. Zhao J, Ye X, Zhang Z. Syndecan-4 is correlated with disease activity and serological characteristic of rheumatoid arthritis. Adv Rheumatol. 2022 Jun 20;62(1):21.
9. Zhao J, Zhang Z. Effective therapy of pirfenidone in a patient with idiopathic retroperitoneal fibrosis: report of a case. Clin Rheumatol. 2023 Feb;42(2):591-595.
10. Zhao J, Huang H, Wang Y, Deng X, Geng Y, Zhang X, Ji L, Song Z, Zhang Z. Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis. Mayo Clin Proc. 2024 Jan;99(1):26-38.
性别:女
职称:副教授 、 副主任医师
导师类别:硕士研究生导师
所属院系:北京大学第一临床医学院
所属专业: 内科学(风湿病)
邮箱 : Juanzi810819@163.com
工作电话 : 010-83575130
颁测谤61促进类风湿关节炎发病的机制研究